CuraTeQ Biologics' EMA GMP certification marks a key milestone in Aurobindo Pharma's expansion into biosimilars, with three ...

Lawyers representing a former boxer charged with serious drug trafficking offences are challenging the legality of the US ...

We recently published a list of 10 Top Performing European Stocks Heading into 2025. In this article, we are going to take a ...

Tharimmune, Inc. (NASDAQ:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today ...

In the wake of an unfavorable advisory committee meeting in September, Intercept Pharmaceuticals’ bid to win full approval ...

Research and development expenses increased to $17.0 million for the three months ended September 30, 2024 from $15.4 million for the three months ended September 30, 2023 primarily due to ...

Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...

MIPLYFFA was further granted Orphan Medicinal Product designation by the European Medicines Agency (EMA) for the treatment of NPC. MIPLYFFA is indicated for use in combination with miglustat for the ...

the development of new drugs, and the European policy research of Chinese herbal medicine. The collaboration between GZUCM and the Royal Melbourne Institute of Technology in Australia has led to the ...

Intercept’s US president Vivek Devaraj said the pharma company still believes in the evidence supporting the liver disease ...

Trump will damage U.S. democracy and global stability, but infighting among his coalition is likely to limit his ...

As per the World Economic Forum, European households continue to save at their highest ... that is engaged in developing a ...